Table 3 Baseline and changes in the proportions of immune cell subsets from baseline to week 12 after pitavastatin treatment vs. placebo baseline

55.50 (50.40–60.89)

− 2.10 (− 8.67–6.60)

−0.30 (− 7.50–16.00)

0.241

38.70 (19.91–45.93)

0.96 (− 9.07 –8.37)

0.12 (− 14.80 –6.83)

0.101

19.72 (9.20–22.01)

− 0.78 (− 4.90–6.34)

1.66 (− 2.98–9.32)

0.134

0.84 (0.46–1.64)

− 0.07 (− 0.47–0.39)

0.04 (− 0.24–0.88)

0.205

1.37 (0.86–1.95)

− 0.27 (− 0.47–0.24)

0.02 (− 0.35–0.68)

0.049

8.28 (3.90–11.59)

− 0.35 (− 3.06–2.21)

0.90 (− 1.24–5.45)

0.073

6.08 (1.75–7.97)

0.04 (− 1.12 – 2.65)

0.66 (− 0.91–2.96)

0.966

3.37 (1.07–4.27)

− 0.23 (− 1.06–0.79)

0.23 (− 0.92–1.64)

0.022

0.76 (0.39–1.04)

0.09 (0.00–0.42)

0.23 (0.06 – 0.52)

0.097

17.79 (8.51 – 21.32)

− 0.61 (− 4.02–3.47)

0.73 (− 3.96–5.20)

0.252

2.93 (1.64–3.48)

− 0.53 (− 1.08–0.59)

− 0.34 (− 1.26–0.83)

0.160

3.35 (2.38–5.01)

0.11 (− 0.92–1.59)

0.55 (− 0.50–1.76)

0.364

2.66 (1.26–5.74)

− 0.41 (− 1.00–0.16)

0.06 (− 0.72–1.33)

0.145

5.07 (2.06–8.34)

0.60 (− 1.35–3.04)

− 0.12 (− 0.93–1.74)

0.703

2.88 (0.94 – 4.80)

− 0.17 (− 0.94 – 0.62)

− 0.01 (− 1.11–1.49)

0.426

3.46 (2.66–4.11)

1.07 (− 1.12 –1.64)

0.61 (− 0.76–1.92)

0.313

1.65 (0.90–2.71)

0.72 (− 0.60–1.81)

0.65 (− 0.40–2.18)

0.569

0.08 (0.04–0.12)

− 0.01 (− 0.05–0.03)

0.00 (− 0.03–0.05)

0.966

0.31 (0.20–0.47)

0.03 (− 0.15 –0.)

0.02 (− 0.11–0.17)

0.326

0.02 (0.01–0.03)

0.00 (− 0.01 –0.02)

0.00 (− 0.01–0.02)

0.490